Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies-Reference-Cited by-同舟云学术

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies

Published:2014-04-30 Issue:7 Volume:23 Page:735-744
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Beigel Florian¹,Steinborn Anni¹,Schnitzler Fabian¹,Tillack Cornelia¹,Breiteneicher Simone¹,John Jestinah Mahachie²³,Van Steen Kristel²³,Laubender Rüdiger P.⁴⁵⁶,Göke Burkhard¹,Seiderer Julia¹,Brand Stephan¹,Ochsenkühn Thomas¹

Affiliation:

1. Department of Medicine II; University Hospital Munich-Grosshadern, Ludwig-Maximilians-University Munich; Munich Germany

2. Systems and Modeling Unit, Montefiore Institute; University of Liege; Liege Belgium

3. Bioinformatics and Modeling, GIGA-R; University of Liege; Liege Belgium

4. Institute of Medical Informatics, Biometry and Epidemiology (IBE); Ludwig-Maximilians-University Munich; Munich Germany

5. German Cancer Consortium (DKTK); Heidelberg Germany

6. German Cancer Research Center (DKFZ); Heidelberg Germany

Funder

Deutsche Forschungsgemeinschaft

Else Kröner-Fresenius-Stiftung

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.3621/fullpdf

Reference49 articles.

1. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease;Rahier;J Crohns Colitis,2009

2. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections;Schneeweiss;Aliment Pharmacol Ther,2009

3. Risk factors for opportunistic infections in patients with inflammatory bowel disease;Toruner;Gastroenterology,2008

4. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease;Steenholdt;J Crohns Colitis,2012

5. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate;Sandborn;Am J Gastroenterol,1996

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

3. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation;Biomedicine & Pharmacotherapy;2023-12

4. Development of innovative methodology for determination of 6-thioguanine in whole blood erythrocytes by HPLC–PDA-based technique for medical diagnostics purposes;Scientific Reports;2023-08-29

5. Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study;European Journal of Gastroenterology & Hepatology;2023-07-31